Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Sarcosine as a potential prostate cancer biomarker--a review.

Cernei N, Heger Z, Gumulec J, Zitka O, Masarik M, Babula P, Eckschlager T, Stiborova M, Kizek R, Adam V.

Int J Mol Sci. 2013 Jul 4;14(7):13893-908. doi: 10.3390/ijms140713893. Review.

2.

Is sarcosine a biomarker for prostate cancer?

Issaq HJ, Veenstra TD.

J Sep Sci. 2011 Dec;34(24):3619-21. doi: 10.1002/jssc.201100572. Epub 2011 Oct 19.

PMID:
22009695
3.

Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.

Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM.

Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762. Erratum in: Nature. 2013 Jul 25;499(7459):504.

4.

[Analysis of the metabolome suggests a major potential role of sarcosine in the progression of cancer of the prostate].

Darbon JM.

Bull Cancer. 2009 Apr;96(4):355-6. French. No abstract available.

PMID:
19562840
5.

A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer.

Cao DL, Ye DW, Zhang HL, Zhu Y, Wang YX, Yao XD.

Prostate. 2011 May 15;71(7):700-10. doi: 10.1002/pros.21286. Epub 2010 Oct 18.

PMID:
20957673
6.

Plasma sarcosine does not distinguish early and advanced stages of prostate cancer.

Bohm L, Serafin AM, Fernandez P, Van der Watt G, Bouic PJ, Harvey J.

S Afr Med J. 2012 Jun 28;102(8):677-9.

PMID:
22831945
7.

Novel biomarkers and therapeutic targets for prostate cancer.

Williams RM, Naz RK.

Front Biosci (Schol Ed). 2010 Jan 1;2:677-84. Review.

PMID:
20036976
8.

Metabolomic signatures of aggressive prostate cancer.

McDunn JE, Li Z, Adam KP, Neri BP, Wolfert RL, Milburn MV, Lotan Y, Wheeler TM.

Prostate. 2013 Oct;73(14):1547-60. doi: 10.1002/pros.22704. Epub 2013 Jul 3.

9.

Innovative biomarkers for prostate cancer early diagnosis and progression.

You J, Cozzi P, Walsh B, Willcox M, Kearsley J, Russell P, Li Y.

Crit Rev Oncol Hematol. 2010 Jan;73(1):10-22. doi: 10.1016/j.critrevonc.2009.02.007. Epub . Review.

PMID:
19328712
10.

Advances in biomarkers for the early diagnosis of prostate cancer.

Cao DL, Yao XD.

Chin J Cancer. 2010 Feb;29(2):229-33. Review.

11.

Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression.

Jentzmik F, Stephan C, Lein M, Miller K, Kamlage B, Bethan B, Kristiansen G, Jung K.

J Urol. 2011 Feb;185(2):706-11. doi: 10.1016/j.juro.2010.09.077. Epub 2010 Dec 18.

PMID:
21168877
12.

Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine.

Cao DL, Ye DW, Zhu Y, Zhang HL, Wang YX, Yao XD.

Prostate Cancer Prostatic Dis. 2011 Jun;14(2):166-72. doi: 10.1038/pcan.2011.2. Epub 2011 Feb 15.

PMID:
21321584
13.

Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.

Katafigiotis I, Tyritzis SI, Stravodimos KG, Alamanis C, Pavlakis K, Vlahou A, Makridakis M, Katafigioti A, Garbis SD, Constantinides CA.

BJU Int. 2012 Dec;110(11 Pt B):E688-93. doi: 10.1111/j.1464-410X.2012.11501.x. Epub 2012 Sep 28.

14.

Sarcosine as a potential prostate cancer biomarker and therapeutic target.

Baum CE, Price DK, Figg WD.

Cancer Biol Ther. 2010 Mar 1;9(5):341-2. Epub 2010 Mar 26. No abstract available.

15.

Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.

Ornstein DK, Rayford W, Fusaro VA, Conrads TP, Ross SJ, Hitt BA, Wiggins WW, Veenstra TD, Liotta LA, Petricoin EF 3rd.

J Urol. 2004 Oct;172(4 Pt 1):1302-5.

PMID:
15371828
16.

Sensitive determination of the potential biomarker sarcosine for prostate cancer by LC-MS with N,N'-dicyclohexylcarbodiimide derivatization.

Chen J, Zhang J, Zhang W, Chen Z.

J Sep Sci. 2014 Jan;37(1-2):14-9. doi: 10.1002/jssc.201301043. Epub 2013 Dec 2.

PMID:
24293130
17.

The important role of glycine N-methyltransferase in the carcinogenesis and progression of prostate cancer.

Song YH, Shiota M, Kuroiwa K, Naito S, Oda Y.

Mod Pathol. 2011 Sep;24(9):1272-80. doi: 10.1038/modpathol.2011.76. Epub 2011 May 13.

18.

Quantification of candidate prostate cancer metabolite biomarkers in urine using dispersive derivatization liquid-liquid microextraction followed by gas and liquid chromatography-mass spectrometry.

Shamsipur M, Naseri MT, Babri M.

J Pharm Biomed Anal. 2013 Jul-Aug;81-82:65-75. doi: 10.1016/j.jpba.2013.03.019. Epub 2013 Apr 10.

PMID:
23624158
19.

Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Koutros S, Meyer TE, Fox SD, Issaq HJ, Veenstra TD, Huang WY, Yu K, Albanes D, Chu LW, Andriole G, Hoover RN, Hsing AW, Berndt SI.

Carcinogenesis. 2013 Oct;34(10):2281-5. doi: 10.1093/carcin/bgt176. Epub 2013 May 22.

20.

Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml.

Lucarelli G, Fanelli M, Larocca AM, Germinario CA, Rutigliano M, Vavallo A, Selvaggi FP, Bettocchi C, Battaglia M, Ditonno P.

Prostate. 2012 Nov;72(15):1611-21. doi: 10.1002/pros.22514. Epub 2012 Mar 16.

PMID:
22430630
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk